Immune system

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, December 2, 2022

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 86,000 shares of its common stock to three employees outside Cullinan Oncology, Incs 2021 Stock Option and Incentive Plan.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 86,000 shares of its common stock to three employees outside Cullinan Oncology, Incs 2021 Stock Option and Incentive Plan.
  • The stock options were granted as an inducement material to the individuals entering into employment with Cullinan, in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Cullinan Oncology, Inc. (NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients with cancer.
  • Learn more about our Company at www.cullinanoncology.com , and follow us on LinkedIn and Twitter .

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022

Retrieved on: 
Friday, December 2, 2022

OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.

Key Points: 
  • OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.
  • Smidt - Centre for Human Drug Research, Leiden, the Netherlands
    For more information, please visit the Congress website, here .
  • AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

Retrieved on: 
Friday, December 2, 2022

HAMPTON, N.J., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple presentations from the barzolvolimab development program will be presented at the 6th GA2LEN Global Urticaria Forum (GUF) being held December 7-8 in Berlin, Germany. Abstracts will be available on the meeting website on December 6th.

Key Points: 
  • Presentations at GUF 2022 are outlined below and include new data from both the Phase 1b 1.5 mg/kg cohort conducted in cold urticaria and long term follow data from the Phase 1b 3.0 mg/kg cohorts conducted in cold urticaria and symptomatic dermographism.
  • The chronic spontaneous urticaria (CSU) and wound healing presentations are Encore presentations and do not include new data.
  • The event will be webcast live and can be accessed by going to the "Events & Presentations" page under the "Investors & Media section of the Celldex Therapeutics website at www.celldex.com .
  • Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.

Genprex to Present at Upcoming December Investor Conference

Retrieved on: 
Friday, December 2, 2022

AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

Key Points: 
  • Ms. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors at the RHK Disruptive Growth Conference.
  • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
  • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
  • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.

EQS-News: First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM

Retrieved on: 
Friday, December 2, 2022

First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM

Key Points: 
  • First Patients Dosed in Phase I/II Trial of Enlivexs Off-the-Shelf Cell Therapy Candidate, AllocetraTM
    The issuer is solely responsible for the content of this announcement.
  • On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra.
  • Enlivexs lead drug candidate, AllocetraTM , was developed as an off-the-shelf cell therapy that reprograms macrophages , the immune cells responsible for killing infected or harmful cells in the body.
  • The next step for this new cell therapy is to test whether these promising preclinical results will translate to human studies.

Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

Retrieved on: 
Thursday, December 1, 2022

The event will feature presentations by the management team and will be followed by a Q&A.

Key Points: 
  • The event will feature presentations by the management team and will be followed by a Q&A.
  • Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.
  • Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
  • These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management.

EQS-News: Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

Retrieved on: 
Thursday, December 1, 2022

Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors

Key Points: 
  • Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
    The issuer is solely responsible for the content of this announcement.
  • The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM.
  • Then, it can turn that macrophage into a pro-tumor ally that will suppress any immune response trying to kill the cancer.
  • The results of early-stage trials may differ significantly from the results of more developed, later-stage trials.

Jarrow Formulas® Introduces Dual-Action Immune Booster

Retrieved on: 
Thursday, December 1, 2022

SANTA FE SPRINGS, Calif., Dec. 1, 2022 /PRNewswire/ -- Jarrow Formulas®, the #1 probiotic brand for customer satisfaction, announced the launch of Immune Booster, formulated with two clinically studied and supported ingredients. The new product supports a healthy immune system and normal digestion.* Available in an easy, single serve stick pack, Immune Booster offers a tasty, orange-flavored, fast-melt powder that quickly dissolves on the tongue without the need for water. 

Key Points: 
  • The fastest growing immunity brand in the natural channellaunches clinically-supported Immune Booster in a convenient, single-serve stick pack format
    SANTA FE SPRINGS, Calif., Dec. 1, 2022 /PRNewswire/ -- Jarrow Formulas , the #1 probiotic brand for customer satisfaction, announced the launch of Immune Booster, formulated with two clinically studied and supported ingredients.
  • "Science has clearly demonstrated that 70% of the immune system is housed in the gut, so we knew in developing Immune Booster, we wanted to focus on the microbiome as the immunity power center," said Hanan Wajih, Chief Marketing Officer of Jarrow Formulas.
  • *
    In addition to PreforPro, DE111 is another clinically supported ingredient in Immune Booster that functions as a spore-forming, immune-supporting probiotic strain.
  • Jarrow Formulas' Immune Booster is available at Amazon and at Jarrow.com .

Mommy's Bliss Survey Highlights Mothers' Concern of Children's Health Leading Up to Holiday Season

Retrieved on: 
Thursday, December 1, 2022

Mommy's Bliss offers expert advice on helping kids stay healthy this holiday as moms state concerns in new survey.

Key Points: 
  • Mommy's Bliss offers expert advice on helping kids stay healthy this holiday as moms state concerns in new survey.
  • According to a recent survey conducted by family health and wellness brand Mommy's Bliss , 72% of moms with kids 10 years old and under say they are concerned about keeping their kids healthy during the upcoming holiday season.
  • With three children under six years old, Dr. Sparks has started preparing her family for the holiday season.
  • Mommy's Bliss Probiotic Drops help support baby's digestive health and immune function*, while Mommy's Bliss Kids Probiotics + Prebiotics Gummies are a great-tasting way to support your kids' immunity and digestive health*.

Lupus Foundation of America Awards Four Grants Supporting Early Career Scientists, Funding Critical Areas of Research

Retrieved on: 
Thursday, December 1, 2022

This year's grantees will focus their research on pediatric lupus, neuropsychiatric lupus and cognitive challenges, and potential new treatment pathways.

Key Points: 
  • This year's grantees will focus their research on pediatric lupus, neuropsychiatric lupus and cognitive challenges, and potential new treatment pathways.
  • Each research study by the CDA grantees will strategically advance the Foundation's research agenda, which includes serving as the leader in supporting childhood lupus research.
  • Lupus is debilitating and destructive and can be fatal, yet research on lupus remains underfunded relative to diseases of similar scope and devastation.
  • Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus.